Understanding Grb7 SH2 Domain and Its Inhibitor G7-18NATE
Author Information
Author(s): Corrine J. Porter, Jacqueline M. Matthews, Joel P. Mackay, Sharon E. Pursglove, Jason W. Schmidberger, Peter J. Leedman, Stephanie C. Pero, David N. Krag, Matthew C. J. Wilce, Jacqueline A. Wilce
Hypothesis
The study investigates how the Grb7 SH2 domain can be inhibited by the cyclic peptide G7-18NATE.
Conclusion
The study provides insights into the structure of the Grb7 SH2 domain and its interaction with the G7-18NATE peptide, which may lead to new cancer therapies.
Supporting Evidence
- The crystal structure of the Grb7 SH2 domain was determined to a resolution of 2.1 Å.
- The G7-18NATE peptide binds to the Grb7 SH2 domain with a binding affinity of approximately 35.7 μM.
- Dimer formation of Grb7 was observed, suggesting a physiological role for the SH2 domain.
Takeaway
Scientists looked at a part of a protein called Grb7 SH2 and how a special peptide can stop cancer cells from growing and moving.
Methodology
The crystal structure of the Grb7 SH2 domain was solved using X-ray crystallography, and binding studies were conducted using isothermal titration calorimetry and NMR spectroscopy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website